Clinical Trial Update: Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) [Phase 2]

View source ↗

Summary

Phase 2 CAPTURE-2 study assessing the efficacy, safety, and pharmacokinetics of M5717 in combination with Pyronaridine for chemoprevention of asymptomatic Plasm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Malaria Falciparum

Drugs mentioned

• M5717 (M5717)
• Pyronaridine (pyronaridine)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Malaria Infection | Phase 2 | Status: COMPLETED | Results posted: 2026-02-06